A randomized phase II trial of concurrent chemoradiation with cetuximab (Erbitux), 5 fluorouracil, hydroxyurea [hydroxycarbamide], and twice-daily radiation (CetuxFHX) versus cetuximab (Erbitux), cisplatin and accelerated radiation with concomitant boost (CetuxPX) after induction chemotherapy in patients with locally advanced head and neck cancer

Trial Profile

A randomized phase II trial of concurrent chemoradiation with cetuximab (Erbitux), 5 fluorouracil, hydroxyurea [hydroxycarbamide], and twice-daily radiation (CetuxFHX) versus cetuximab (Erbitux), cisplatin and accelerated radiation with concomitant boost (CetuxPX) after induction chemotherapy in patients with locally advanced head and neck cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2012

At a glance

  • Drugs Cetuximab; Cisplatin; Fluorouracil; Hydroxycarbamide
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms EPIC
  • Most Recent Events

    • 09 Oct 2012 Planned End Date changed from 1 Jul 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Results were presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 13 Jan 2011 Planned end date changed from 1 Apr 2010 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top